TSE aims to undertake research that helps public and private organizations to address health issues and improve quality and access to care both in France and worldwide. For more than a decade, TSE economists have been studying such diverse topics as healthcare, innovation, aging, pharmaceutical regulation, food and nutrition issues. The set of open questions for economists in the health field is still large. Researchers in economics can develop and use new tools to address questions of regulation and organization of healthcare and innovation.
In 2021, TSE expanded its footprint in this area by creating a Health Center aiming at developing a research of excellence in the field of health economics. Combining TSE’s own expertise with its private and public partners’ financial support and knowledge, TSE Health Center supports a variety of work in the field of health economics. It pulls together different strands of research on health economics including health, healthcare, food, and it encourages multidisciplinary research projects involving economists and researchers with other backgrounds (epidemiology, medicine, pharmacy, psychology, biology…).
- Scientific production: development of new knowledge in the framework of multi-year research cycles resulting in academic publications and often punctuated by scientific conferences and seminars,
- Dissemination of economic knowledge through the production of outreach materials and the organization of events meant to inform practitioners, policy makers or a wider audience, and the participation of researchers in the public debate in France and internationally.
Pharmaceutical industry and regulation
- Objective: Researchers involved in this program seek to provide the best trade-off between maintaining incentives to innovate (with high rewards to new useful medicines) and financing health care expenses. We study how regulatory rules impact profitability and welfare in an international context, and analyze the role of marketing authorizations, detailing effort in fostering access and diffusion of medicines.
- Program leader: Pierre Dubois works on health economics and the economics of the pharmaceutical sector, industrial organization, micro econometrics, consumer demand.
Innovation in health
- Objective: Research work developed in this area is focused on incentive and privacy issues. It includes the design of analytical models and the testing of predictions with existing empirical and experimental data.
- Program leader: Philippe De Donder works on public economics, regulation, and health economics.
Public healthcare, long term care and aging
- Objective: This program aims to offer a better understanding of the complex relationships between the different insurers, and care providers including practitioners, hospitals, or the pharmaceutical industry. Researchers also study the different forms of financing expenses related to aging and age-related dependency.
- Program leader: Jean-Marie Lozachmeur works on public economics, health economics and industrial organization.
Food and healthy behavior economics
- Objective: Researchers involved in this program study the determinants of food behavior with special attention given to the role of socio-economic factors, peer effects, food availability and prices, and the environment. Our work helps assess the impact of food olicies on health and social welfare and understand how businesses and markets respond to policies.
- Program leader: Céline Bonnet works on industrial organization, manufacturers and retailers’ relationships, applied econometrics, consumer behavior. She is a specialist of consumers’ and firms’ behavior in the agrofood chains.
Economics of pandemics
- Objective: The purpose of this program is to identify the consequences of health crisis and the optimal public investment policy to face them. Researchers involved study the cost-benefit issues of the different public policies, as well as the factors of individual behavior and responsibility that influence compliance with public health recommendations. They also investigate the commercial and pricing regulations that should be put in place in a context of drug shortages and increasing demand for care.
- Program leader: Nour Meddahi works on financial econometrics, time series modeling, forecasting, risk management, and econometrics.